Evidence map›Paper›PMID 24141650›Full record

ArticleBone marrow transplantation2014

Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

J Chen, R-X Wang, F Chen, A-N Sun, H-Y Qiu, Z-M Jin, X-W Tang, Y Han, Z-Z Fu, G-S He and 3 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03608059 (Shanghai General Hospital Affiliated to Shanghai Jiao Tong University), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03608059 phase4completednot on this mapstarted 2018, after this paper: background citation

Shanghai General Hospital Affiliated to Shanghai Jiao Tong University

TypeinterventionalSponsorShanghai General Hospital, Shanghai Jiao Tong University School of MedicineRan2018 to 2023Enrolled418ConditionsMyeloid TumorArmsATG/PTCy, standard ATG, standard PTCy
3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J Chen1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
R-X Wang1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
F Chen1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
A-N Sun1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
H-Y Qiu1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
Z-M Jin1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
X-W Tang1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
Y Han1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
Z-Z Fu1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
G-S He1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
M Miao1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
X Ma1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.
D-P Wu1] Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China [2] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11-180 days). All surviving patients attained complete haploidentical engraftment except three patients who presented a mixed engraftment with increasing cord blood and decreasing haplo mismatch chimerism during the first 4 months after transplantation. The cumulative incidence of grade II-IV acute GVHD was 20%±0.327% at day+100, and the incidence of chronic GVHD was 19.26%±1.0% at 1 year. The 1-year cumulative incidence of relapse was 19.78%±1%, and the TRM was 16.2%±0.54%. At 1 year, overall survival was 78.6%±7.6% and PFS 64.0%±11.0%. The BU/CY-based conditional regimen showed a significant superiority over TBI/CY on PFS (relative risk=5.012, 95% confidence interval, 1.146-21.927, P=0.032). In conclusion, the co-infusion of an unrelated cord blood unit may potentially improve the outcome of haploidentical allogeneic hematopoietic SCT.

Indexed as

AdolescentAdultCord Blood Stem Cell TransplantationFemaleGraft vs Host DiseaseHumansMaleProspective StudiesTransplantation, HomologousUnrelated DonorsYoung Adult

Identifiers

PMID24141650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.